Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Inclusion criteria

• Patients with RA as defined by the 2010 revised American College of Rheumatology (ACR)
• ACR Class I-III functional status, based on the 1991 revised criteria
• Treated for a minimum of 12 weeks with Methotrexate with a stable dose of MTX for at least 8 weeks prior to screening visit

Exclusion criteria

• Patients less than 18 years of age or minimum legal age
• Prior treatment with any biologic anti-Interleukin 6 (IL-6) or IL-6 Receptor (IL-6R) antagonists
• Use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks prior to screening
• Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks prior to randomization
• Participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer
• Treatment with oral/ biologic DMARDs (disease-modifying antirheumatic drugs), other than MTX, within a certain amount of time prior to screening visit
• Active or suspected TB or at high risk of contracting TB
• Fever, or chronic, persistent, or recurring infections requiring active treatment
• HIV positive

Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.